In patients experiencing excessive bleeding during cardiac surgery, a concentrated blood product containing proteins that ...

A drug developed as an antidote to the antiplatelet agent ticagrelor safely and effectively reversed ticagrelor's ...

People at high risk for recurrent cardiac events following percutaneous coronary intervention (PCI), a procedure to open ...

Three months of dual antiplatelet therapy after PCI may safely balance thrombosis and bleeding risk in both patients with low ...

FDA Approval: The FDA granted full approval for Symvess on December 19, 2024 for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid ...

Platelet spreading and clot contraction are controlled by different pathways. This discovery leads to safer treatments for ...